[Hormone therapy and risk of venous thromboembolism: new insights from the ESTHER study].
Canonico
Marianne
M
Scarabin
Pierre-Yves
PY
D020016:Activated Protein C Resistance / Q000139:chemically induced; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000368:Aged; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006487:Hemostasis / Q000502:physiology; D020249:Hormone Replacement Therapy / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D008099:Liver / Q000378:metabolism; D008593:Menopause; D008875:Middle Aged; D009650:Norpregnanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011278:Pregnanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000453:epidemiology
D004967:Estrogens; D009650:Norpregnanes; D011278:Pregnanes; D011374:Progesterone